2021-04-12T13:39:32Z
2021-04-12T13:39:32Z
2020-11-20
2021-04-12T13:39:32Z
The pathogenesis of muscle atrophy plays a central role in cancer cachexia, and chemotherapy contributes to this condition. Therefore, the present study aimed to evaluate the effects of endurance exercise on time-dependent muscle atrophy caused by doxorubicin. For this, C57 BL/6 mice were subcutaneously inoculated with Lewis lung carcinoma cells (LLC group). One week after the tumor establishment, a group of these animals initiated the doxorubicin chemotherapy alone (LLC + DOX group) or combined with endurance exercise (LLC + DOX + EXER group). One group of animals was euthanized after the chemotherapy cycle, whereas the remaining animals were euthanized one week after the last administration of doxorubicin. The practice of exercise combined with chemotherapy showed beneficial effects such as a decrease in tumor growth rate after chemotherapy interruption and amelioration of premature death due to doxorubicin toxicity. Moreover, the protein degradation levels in mice undergoing exercise returned to basal levels after chemotherapy; in contrast, the mice treated with doxorubicin alone experienced an increase in the mRNA expression levels of the proteolytic pathways in gastrocnemius muscle (Trim63, Fbxo32, Myostatin, FoxO). Collectively, our results suggest that endurance exercise could be utilized during and after chemotherapy for mitigating muscle atrophy promoted by doxorubicin and avoid the resumption of tumor growth.
Article
Published version
English
Etiologia; Quimioteràpia; Càncer de pulmó; Etiology; Chemotherapy; Lung cancer
MDPI
Reproducció del document publicat a: https://doi.org/10.3390/cancers12113466
Cancers, 2020, vol. 12, num. 11, p. 3466
https://doi.org/10.3390/cancers12113466
cc-by (c) Alves de Lima Jr., Edson et al., 2020
http://creativecommons.org/licenses/by/3.0/es